Concert recording 2014-04-27

[Track 01]. Introduction and dance / J.E. Barat -- [Track 02]. Three miniatures. Allegro / Anthony Plog -- [Track 03]. Three miniatures. Adagio / Anthony Plog -- [Track 04]. Three miniatures. Allegro / Anthony Plog -- [Track 05]. Concerto. Introduction-allegro / Corrado Maria Saglietti -- [Track 06]. Concerto. Adagio / Corrado Maria Saglietti -- [Track 07]. Suite for unaccompanied tuba. March / Walter Hartley -- [Track 08]. Suite for unaccompanied tuba. Valse / Walter Hartley -- [Track 09]. Suite for unaccompanied tuba. Sarabande / Walter Hartley -- [Track 10]. Suite for unaccompanied tuba. Galop / Walter Hartley -- [Track 11]. Sonata for euphonium and piano childs play / Barbara York -- [Track 12]. Apres un Reve / Gabriel Faure ; translated by Mead -- [Track 13]. Concerto in one movement / Alexei Lebedev -- [Track 14]. Tuba suite. Prelude / Gordon Jacob -- [Track 15]. Tuba suite. Hornpipe / Gordon Jacob -- [Track 16]. Tuba suite. Sarabande / Gordon Jacob -- [Track 17]. Tuba suite. Bouree / Gordon Jacob -- [Track 18]. Tuba suite. Intrada ; Mazurka / Gordon Jacob -- [Track 19]. Fantasia di concerto / Eduardo Boccalari

Concert recording 2014-11-18

[Track 01]. Mars from The planets / Gustav Holst ; arranged by David Butler -- [Track 02]. Consortium / John Cheetham -- [Track 03]. Axis / Kevin McKenzie -- [Track 04]. Scherzo from A midsummer night\u27s dream / Felix Mendelssohn ; arranged by Michael Forbes -- [Track 05]. Nocturne / Rimsky-Korsakov -- [Track 06]. Ave Maria / Franz Biebl ; arranged by Mark Jenkins -- [Track 07]. Fearful symmetry / Kenyon Wilson

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

Abstract Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low copy number (MP-LCN) as an MRD transcript level <1% to 2% with a <1-log change between any 2 positive samples collected after the end of treatment (EOT). Because the clinical impact of MP-LCN is unknown, we sought to characterize outcomes in patients with persistent NPM1mut MRD after EOT and identify factors associated with disease progression. Consecutive patients with newly diagnosed NPM1mut AML who received ≥2 cycles of intensive chemotherapy were included if bone marrow was NPM1mut MRD positive at the EOT, and they were not transplanted in first complete remission. One hundred patients were followed for a median of 23.5 months; 42% remained free of progression at 1 year, either spontaneously achieving complete molecular remission (CRMRD−; 30%) or retaining a low-level NPM1mut transcript (12% for ≥12 months and 9% at last follow-up). Forty percent met the criteria for MP-LCN. Preemptive salvage therapy significantly prolonged relapse-free survival. Risk factors associated with disease progression were concurrent FLT3-internal tandem duplication at diagnosis and suboptimal MRD response (NPM1mut reduction <4.4-log) at EOT